Khepri other research news

The South San Francisco company received two Phase I SBIR grants to develop drugs for wound healing and neurologic diseases based on proteases and protease inhibitors.

A $67,000 grant from the NIH's Arthritis and Muscoskelatal and Skin Diseases division will fund the study of the protease inhibitory activity of agrin, a protein thought to be important in the formation and maintenance of the neuromuscular junction and in the regulation of protease activity associated with neurodegenerative diseases. ...